Long term outcomes of patients with skull-base low-grade chondrosarcoma and chordoma patients treated with pencil beam scanning proton therapy

2016 ◽  
Vol 120 (1) ◽  
pp. 169-174 ◽  
Author(s):  
Damien C. Weber ◽  
Robert Malyapa ◽  
Francesca Albertini ◽  
Alessandra Bolsi ◽  
Ulrike Kliebsch ◽  
...  
2015 ◽  
Vol 18 (2) ◽  
pp. 236-243 ◽  
Author(s):  
Damien C. Weber ◽  
Shahed Badiyan ◽  
Robert Malyapa ◽  
Francesca Albertini ◽  
Alessandra Bolsi ◽  
...  

2015 ◽  
Vol 17 (suppl 8) ◽  
pp. viii3.4-viii3 ◽  
Author(s):  
Damien Charles Weber ◽  
Shahed Badiyan ◽  
Tony Lomax ◽  
Robert Malyapa ◽  
Alessandra Bolsi ◽  
...  

2018 ◽  
Vol 129 (6) ◽  
pp. 1313-1317 ◽  
Author(s):  
Jonathan E. Leeman ◽  
Nancy Y. Lee ◽  
Ying Zhou ◽  
Brian Neal ◽  
Kevin Sine ◽  
...  

2017 ◽  
Vol 99 (5) ◽  
pp. 1190-1198 ◽  
Author(s):  
Fritz R. Murray ◽  
James W. Snider ◽  
Alessandra Bolsi ◽  
Antony J. Lomax ◽  
Marc Walser ◽  
...  

2020 ◽  
Vol 67 (12) ◽  
Author(s):  
Pei S. Lim ◽  
Sébastien Tran ◽  
Stephanie G.C. Kroeze ◽  
Alessia Pica ◽  
Jan Hrbacek ◽  
...  

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii458-iii458
Author(s):  
Pei Shuen Lim ◽  
Sébastien Tran ◽  
Stephanie G C Kroeze ◽  
Alessia Pica ◽  
Jan Hrbacek ◽  
...  

Abstract BACKGROUND The use of highly conformal proton therapy in adolescents and young adults (AYAs) for management of brain/skull-base tumours is becoming increasingly common. This study aims to assess the long-term clinical outcomes, prognostic factors and employment status of AYAs (15–39 years) treated with pencil-beam-scanning proton-therapy (PT). METHODS Between 1997–2018, 176 AYAs were treated with PT at the Paul Scherrer Institute. Median age was 30 years (range, 15–39) and the male/female ratio was 0.8. RESULTS After a median follow-up of 66 months (range, 12–236), 24 (13.6%) local failures and 1 (0.6%) distant failure were observed between 6 and 152 months after PT. The most common histologies treated were chordomas/chondrosarcomas (61.4%), followed by meningiomas (14.2%) and gliomas (15.3%). The 6-year local-control (LC), distant-progression-free survival and overall-survival (OS) rate was 83.2%, 97.4% and 90.2% respectively. On univariate analysis, age ≥24 years was a negative prognostic factor for LC. Recurrent disease, infratentorial tumours and low-grade-glioma histology were poor prognostic factors for both LC and OS. The 6-year ≥G3 PT-related late toxicity-free survival was 88.5%. The moderate-high grade late toxicity crude rates were 37.8% G2, 12.2% G3, 0.6% G4 and 0.6% G5. No secondary malignancies were observed. The unemployment rate was 7.3% at PT, rising to 25.3% at survivorship. High-grade(≥G3) toxicity rate in the unemployed vs employed group was 21% vs 8.5%. CONCLUSION PT is an effective treatment for AYAs with brain/skull-base tumours with good tumour control and acceptable long-term toxicity. Despite having satisfactory clinical outcomes, around 1 in 4 AYAs surviving brain/skull base tumours are unemployed.


2020 ◽  
Vol 15 (1) ◽  
Author(s):  
Lucas Basler ◽  
Robert Poel ◽  
Christina Schröder ◽  
Alessandra Bolsi ◽  
Antony Lomax ◽  
...  

Abstract Background Despite combined modality treatment involving surgery and radiotherapy, a relevant proportion of skull-base chordoma and chondrosarcoma patients develop a local recurrence (LR). This study aims to analyze patterns of recurrence and correlate LR with a detailed dosimetric analysis. Methods 222 patients were treated with proton radiotherapy for chordoma (n = 151) and chondrosarcoma (n = 71) at the PSI between 1998 and 2012. All patients underwent surgery, followed by pencil-beam scanning proton therapy to a mean dose of 72.5 ± 2.2GyRBE. A retrospective patterns of recurrence analysis was performed: LR were contoured on follow-up MRI, registered with planning-imaging and the overlap with initial target structures (GTV, PTVhigh-dose, PTVlow-dose) was calculated. DVH parameters of planning structures and recurrences were calculated and correlated with LR using univariate and multivariate cox regression. Results After a median follow-up of 50 months, 35 (16%) LR were observed. Follow-up MRI imaging was available for 27 (77%) of these recurring patients. Only one (3.7%) recurrence was located completely outside the initial PTV (surgical pathway recurrence). The mean proportions of LR covered by the initial target structures were 48% (range 0–86%) for the GTV, 70% (range 0–100%) for PTVhigh and 83% (range 0–100%) for PTVlow. In the univariate analysis, the following DVH parameters were significantly associated with LR: GTV(V < 66GyRBE, p = 0.01), GTV(volume, p = 0.02), PTVhigh(max, p = 0.02), PTVhigh(V < 66GyRBE, p = 0.03), PTVhigh(V < 59GyRBE, p = 0.02), PTVhigh(volume, p = 0.01) and GTV(D95, p = 0.05). In the multivariate analysis, only histology (chordoma vs. chondrosarcoma, p = 0.01), PTVhigh(volume, p = 0.05) and GTV(V < 66GyRBE, p = 0.02) were independent prognostic factors for LR. Conclusion This study identified DVH parameters, which are associated with the risk of local recurrence after proton therapy using pencil-beam scanning for patients with skull-base chordoma and chondrosarcoma.


Sign in / Sign up

Export Citation Format

Share Document